SCHEMBL5983176

SCHEMBL5983176

CSc1ncnc2c1[nH]c(=O)n2[C@H]1C[C@@H](O)[C@H](CO)O1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 1/20 0.44
▸ ADORA3 P0DMS8 1/20 0.44
▸ ADORA2A P29274 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ TK1 P04183 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ TP53 P04637 1/20 0.42
▸ TK2 O00142 1/20 0.42
▸ ATG7 O95352 2/20 0.42
▸ ALOX12 P18054 1/20 0.41
▸ ADRA1A P35348 1/20 0.41
▸ ADRB1 P08588 1/20 0.40
▸ DNMT1 P26358 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ PMP22 Q01453 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5983171 1.00 HIF1A (0.44) HIF1AADORA3ADORA2ASMN1; SMN2TK1
SCHEMBL443066 0.85 TK1 (0.46) HIF1AADORA3ADORA2ASMN1; SMN2TK1
SCHEMBL529559 0.84 ADORA3 (0.53) HIF1AADORA3ADORA2ASMN1; SMN2TK1
SCHEMBL439799 0.84 ADORA3 (0.53) HIF1AADORA3ADORA2ASMN1; SMN2TK1
SCHEMBL27054384 0.84 ADORA3 (0.53) HIF1AADORA3ADORA2ASMN1; SMN2TK1
SCHEMBL5982026 0.84 LMNA (0.45) HIF1AADORA3ADORA2ASMN1; SMN2TK1
SCHEMBL439797 0.84 ADORA3 (0.53) HIF1AADORA3ADORA2ASMN1; SMN2TK1
SCHEMBL5982753 0.84 ADORA3 (0.53) HIF1AADORA3ADORA2ASMN1; SMN2TK1
SCHEMBL5982748 0.84 ADORA3 (0.53) HIF1AADORA3ADORA2ASMN1; SMN2TK1
SCHEMBL5982032 0.84 LMNA (0.45) HIF1AADORA3ADORA2ASMN1; SMN2TK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1634888-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2006-03-15 — — EP disclosed
EP-1600452-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2005-11-30 — — EP disclosed
EP-1600451-A2 Synthesis of 2'-deoxy-l-nucleosides Pharmasset Limited (US) 2005-11-30 — — EP disclosed
US-20050090660-A1 2'-deoxy-L-nucleosides PHARMASSET, INC. 2005-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090660-A1 2'-deoxy-L-nucleosides CCNH, ADAR, NSUN2 HIF1A 2249/4885ADORA3 14/4885ADORA2A 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback